AXO Science

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services – from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.

Our Discovery services include conducting early-stage research from target identification to delivery of drug candidates for further development. Development services encompass activities from pre-clinical to clinical trials including Drug Substance Development (DSP), Drug Product Development (DPD) and associated services to demonstrate safety, tolerability and efficacy of the selected drug candidate.

Our Manufacturing services for small and large molecules include cGMP-compliant facilities for clinical supplies, registration batches as well as commercial volumes through our API manufacturing plant & disposable Biologics manufacturing facility.

Driving our innovative culture is our highly qualified team of 4200 scientists supported by state-of-the-art infrastructure and market-leading technology. Our scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security & quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.

With 2 Mn sq ft of specialist discovery, development & manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. Smaller and virtual companies, non-profit institutions, academic centers and start-ups also collaborate with us for their research-related requirements.

Write to us at bdc@syngeneintl.com

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life.

AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use.

AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises.

AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

Accelrys was founded in 2001 from the combination of five companies: Molecular Simulations Inc, Synopsys Scientific Systems, Oxford Molecular, the Genetics Computer Group (GCG), and Synomics Ltd. In 2004, Accelrys acquired SciTegic, the developer of Pipeline Pilot data pipelining and scientific workflow authoring software.

In July 2010, Accelrys merged with Symyx Technologies, Inc., combining the Accelrys portfolio of scientific informatics solutions with the market-leading Symyx electronic laboratory notebook (ELN). The Accelrys-Symyx merger also extended Accelrys’ product offerings with certain software and content products from MDL Information Systems, Inc., which Symyx had acquired from Elsevier, Inc. in 2007. MDL had been a premier scientific software vendor for over 25 years with critical software solutions deployed across approximately 750 organizations.

Subsequently, Accelrys further extended its scientific informatics and product lifecycle management capabilities through the acquisitions of:
• Contur Software
• VelQuest Corp
• Aegis Analytical Corp
• Vialis AG
• ChemSW, Inc.
• QUMAS

Accelrys’ deliberate merger and acquisition strategy made the company one of the largest, most comprehensive scientific informatics companies in the world with a clear focus on creating, driving and delivering wide-ranging scientific product lifecycle management solutions across the research, development, QA/QC and manufacturing phases of product development.

After acquiring Accelrys on April 29, 2014, Dassault Systèmes announced the creation of BIOVIA on May 21, 2014, describing the new company as a combination of Accelrys’ leading life sciences and materials sciences solutions with Dassault Systèmes activities in BioIntelligence and its collaborative 3DEXPERIENCE® platform.

Advanced Molecular Technologies Pty Ltd (AMT) is a contract research organisation (CRO) established in 2005, specialising in medicinal chemistry and custom organic synthesis. The provided services involve the synthesis of target molecules, the manufacturing (larger-scale) of chemical materials, analytical chemistry, chemical method development and optimisation, drug discovery and synthetic organic research.

AMT is also a manufacturer and supplier of chemicals in Victoria, Australia, distributing specialty products to partners, institutions and companies worldwide.

AMT has extensive experience in organoboron, organosilicon, PEG-linkers and fluorophore technology, with many of these discrete molecules available for purchase on their website. More recently, AMT is spinning-out its own initiatives through novel technology developed within the pharmaceutical and veterinary industries.

Equipped with a 400 MHz NMR machine, HPLC, GC, FT-IR and several other analytical pieces of equipment, AMT also readily provides analytical services to the chemical industry.

AlphaGenix is a life science company that develops novel products and technologies for basic and clinical research with a particular emphasis on stem cell biology, biomaterials and regenerative medicine.

The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models.

AlphaGenix has its main laboratory and corporate offices at the Purdue Research Park in West Lafayette, IN. Its biomaterials facility is located in Sioux Falls, SD with The University of South Dakota Biomedical Engineering Department as part of an ongoing research collaboration. The laboratories include a state-of-the-art molecular and cell biology facility, a Class 100 cleanroom for manufacturing and advanced scientific imaging equipment.